Zimmer Biomet Holdings Inc traded at $89.91 this Friday February 6th, increasing $1.18 or 1.33 percent since the previous trading session. Looking back, over the last four weeks, Zimmer Biomet Holdings gained 2.98 percent. Over the last 12 months, its price fell by 10.92 percent. Looking ahead, we forecast Zimmer Biomet Holdings Inc to be priced at 84.39 by the end of this quarter and at 76.83 in one year, according to Trading Economics global macro models projections and analysts expectations.
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.